Research programme: vascular disease therapeutics - TI Pharma
Latest Information Update: 27 Jun 2017
At a glance
- Originator Actelion Pharmaceuticals; Erasmus MC; Maastricht University; TI Pharma
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Vascular disorders
Most Recent Events
- 16 Jun 2017 Actelion Pharmaceuticals has been acquired by Janssen Pharmaceuticals
- 16 Jul 2016 No recent reports of development identified for research development in Vascular-disorders in Netherlands
- 17 Nov 2009 Early research in Vascular disorders in Netherlands (unspecified route)